Intra-abdominal Infections Clinical Trial
Official title:
A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone
The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04240288 -
Procalcitonin Guided Antibiotic Therapy
|
N/A | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Terminated |
NCT03354754 -
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
|
Phase 2 | |
Completed |
NCT00965848 -
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
|
Phase 4 | |
Completed |
NCT01506271 -
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
|
Phase 2 | |
Completed |
NCT05628493 -
Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
|
||
Completed |
NCT02442596 -
Abdominal SepsiS Study: Epidemiology of Etiology and Outcome
|
N/A | |
Recruiting |
NCT04094818 -
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
|
||
Withdrawn |
NCT05639504 -
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
|
||
Completed |
NCT00827541 -
Post-Authorization Study Evaluating Safety Of Tigecycline
|
N/A | |
Completed |
NCT01789905 -
Tygacil Drug Use Investigation
|